$GE

GE HealthCare buys SOFIE Biosciences for $945 M to establish 'Final Mile' footprint for PET Radiopharmaceutical Supply in US

GE HealthCare agreed to buy SOFIE Biosciences for $945 million in cash, expanding its US PET radiopharmaceutical supply network. The deal, expected to close in H1 2027, adds 15 CMO sites and 21 cyclotrons, enhancing GE HealthCare's theranostics capabilities. SOFIE will join GE HealthCare's PDx segment.

Original reporting
Published Oct 8, 2026, 7:05 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 7:55 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
GE HealthCare buys SOFIE Biosciences for $945 M to establish 'Final Mile' footprint for PET Radiopharmaceutical Supply in US — source image
Decision brief

The 30-second read

$GENeutralHigh
01

Why it matters

The deal adds a final‑mile capability for PET radiopharmaceuticals, a high‑growth niche in precision medicine.

02

Market read

The acquisition could enhance GE's competitive position in theranostics while requiring significant cash, likely influencing its stock price in the short term.

03

What to watch

Regulatory approval risk for the integration of a CMO and potential competition from other radiopharma providers.

Relevance 9/10Novelty 9/10Timing: today

Background

GE HealthCare is a major US‑listed medical‑technology company expanding its diagnostics portfolio.

Company-level read

Ticker impact

$GENeutralHigh confidence
Context

GE HealthCare announced a definitive agreement to acquire SOFIE Biosciences for $945 million in cash.

Expected impact

likely modest pressure as investors price in the $945M cash payment and integration risk

Evidence & confidence

Large cash deal for a private CMO; market typically reacts with slight downside on the acquirer.

Market effects

Expands GE HealthCare's footprint in the growing PET radiopharmaceutical and theranostics market.

Strengthens US domestic supply chain for PET agents, potentially benefiting related imaging equipment makers.

Positions GE as a more integrated player in global precision‑medicine supply chains.

Counterpoint

The cash outlay may strain GE's balance sheet and dilute earnings, outweighing strategic benefits.

Key entities

  • GE HealthCare

    US‑listed medical‑technology firm (ticker GE).

  • SOFIE Biosciences

    US‑based contract manufacturing organization for PET radiopharmaceuticals.

Related articles

$GEMed

Defense Backlog Could Be A Key Watch For GE Stock

General Electric reported a Defense & Propulsion Technologies backlog exceeding $30 billion and a defense book-to-bill ratio of 1.7x, indicating strong order intake. Analysts suggest this backlog could stabilize revenues amid commercial aviation fluctuations and supply chain pressures. GE's investment narrative hinges on growing earnings and efficiency, with risks tied to supply chains and program profitability.

$GEMed

GE Vernova Stocks Sink 3.4% Despite First U.S. Small-Reactor Per

GE Vernova's shares fell 3.42% to $994 on October 7, despite securing a U.S. construction permit for its BWRX-300 small nuclear reactor. The permit, issued by TVA for the Clinch River project, is a regulatory milestone, but commercial success remains uncertain. GE Vernova aims to leverage repeat business from the design, but investors await funded projects and equipment orders to validate the opportunity.

$GEHighAI 9/10

GE HealthCare to Acquire SOFIE Biosciences for $945 Mn

GE HealthCare agreed to acquire SOFIE Biosciences from Trilantic North America for $945 million in cash, expanding its radiopharmaceutical supply chain. The deal, expected to close in H1 2027, includes 15 U.S. manufacturing sites and rights to FAPI-74. GE HealthCare anticipates revenue growth and margin expansion from the acquisition.

$GEHighAI 9/10

GE HealthCare to Snap Up Sofie Biosciences for $945M

GE HealthCare agreed to acquire Sofie Biosciences for $945M, expected to close by mid-2027. The deal aims to bolster GE's radiopharmaceutical market position, adding US manufacturing and distribution for PET products. Sofie's FAPI-74 rights in the US are included. GE HealthCare projects revenue and earnings growth from the acquisition, with analyst Ryan Zimmerman calling it infrastructure-focused. This follows Curium's $7B acquisition of Lantheus in August.

$GEMed

Tenova and GE Vernova selected to supply world’s largest electric arc furnace to Nippon Steel’s Yawata Works

Nippon Steel has selected Tenova and GE Vernova to supply the world's largest Consteel® Electric Arc Furnace for its Yawata Area, Kyushu Works. The project supports Nippon Steel's decarbonization strategy, with Tenova providing the furnace and GE Vernova supplying the power system. This marks a significant step in the global shift towards EAF steelmaking, driven by environmental pressures and technological advancements.